EUVIMEDEUVIMED entdecken
Open Access

How I treat erythropoietic protoporphyria and X-linked protoporphyria

Rebecca Karp Leaf iD, Amy K Dickey iD

Blood · 2023

DOI: 10.1182/blood.2022018688 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, 2023. Verfasst von Rebecca Karp Leaf und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA. Hauptthemen laut MEDLINE: Liver Diseases, Protoporphyria, Erythropoietic, Photosensitivity Disorders. Die Arbeit wurde bisher 9-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Erythropoietic protoporphyria (EPP) is an inherited cutaneous porphyria caused by reduced expression of ferrochelatase, the enzyme that catalyzes the final step in heme biosynthesis. The resultant accumulation of protoporphyrin IX leads to severe painful cutaneous photosensitivity, as well as potentially life-threatening liver disease in a small percentage of patients. X-linked protoporphyria (XLP) is similar to EPP clinically, but results from increased activity of δ-aminolevulinic acid synthase 2 (ALAS2), the first step in heme biosynthesis in the bone marrow, and also causes protoporphyrin accumulation. Although historically the management of EPP and XLP (collectively termed protoporphyria) centered around avoidance of sunlight, novel therapies have recently been approved or are in development, which will alter the therapeutic landscape for these conditions. We present three patient vignettes highlighting key treatment considerations in patients with protoporphyria including (1) approach to photosensitivity, (2) managing iron deficiency in protoporphyria, and (3) understanding hepatic failure in protoporphyria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver DiseasesProtoporphyria, ErythropoieticPhotosensitivity DisordersGenetic Diseases, X-LinkedHemeHumans5-Aminolevulinate SynthetaseProtoporphyrinsFerrochelatase

Substanzen

HemeProtoporphyrinsFerrochelatase5-Aminolevulinate Synthetase

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA.
  • Harvard Medical School, Boston, MA.
  • Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA.

ORCID-Profile: Rebecca Karp Leaf, Amy K Dickey

Förderung

  • NIAMS NIH HHS
  • NIDDK NIH HHS

Zitieren

APA

Leaf, R. K., & Dickey, A. K. (2023). How I treat erythropoietic protoporphyria and X-linked protoporphyria. Blood. https://doi.org/10.1182/blood.2022018688

Vancouver

Leaf RK, Dickey AK. How I treat erythropoietic protoporphyria and X-linked protoporphyria. Blood. 2023. doi:10.1182/blood.2022018688

BibTeX
@article{Leaf2023,
  author = {Leaf, Rebecca Karp and Dickey, Amy K},
  title = {How I treat erythropoietic protoporphyria and X-linked protoporphyria},
  journal = {Blood},
  year = {2023},
  doi = {10.1182/blood.2022018688}
}
Kostenlos starten →